Porcine Reproductive & Respiratory Syndrome roadmap:
Vaccines
Roadmap for development of a candidate vaccine for PRRSV
Download PRRSV Vaccine Roadmap8
Attenuated organisms
Dependencies
- 13 Identity of virulence factors
- 14 Identity of immunomodulators
- 15 Host responses to natural infection
Next steps
- 3 Rationally attenuated candidates
- 3A Safety
- 3B Delivery route
- 3C Delivery platform
- 3D Efficacy in challenge model
The generation of rationally attenuated genetically modified PRRSV
Research Question
- To generate organisms that are less virulent in terms of pathological changes that they cause and/or their ability to modulate the host’s immune responses – rationally attenuated vaccine
Research Gaps and Challenges
- That the organisms are stable and can be produced in cell culture
- That they still generate a protective response
Solution Routes
- Generation of infectious cDNA clones
- Generation and characterisation of a range of rationally attenuated organisms (using codon pair deoptimization)
- Immune response to the attenuated organisms
Dependencies
- Identity of Virulence factors and their genes
- Identity of immunomodulators
Projects
What activities are planned or underway?
Immune responses induced by inactivated Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccine in neonate pigs using different adjuvants
Planned Completion date 01/02/2021
Source Countries:
Netherlands
Modified live vaccine strains of porcine reproductive and respiratory syndrome virus cause immune system dysregulation similar to wild strains.
Planned Completion date 12/01/2024
Source Countries:
Netherlands